Soleno Therapeutics Faces Securities Lawsuit Over DCCR Efficacy and Safety Claims

Soleno Therapeutics Faces Legal Battle Over DCCR Efficacy Claims

Soleno Therapeutics, Inc. confronts a securities class action lawsuit initiated by shareholders who acquired stock between March 26, 2025, and November 4, 2025. The lawsuit stems from a disappointing report concerning the company’s lead product, DCCR (made available as VYKAT™ XR), designed to treat hyperphagia in patients with Prader-Willi Syndrome (PWS). This litigation follows a significant drop in the company’s stock price, which tumbled 26% after Soleno disclosed adverse findings regarding the drug's safety and efficacy on November 5, 2025. The reports raise serious concerns about the potential commercial viability of DCCR, questioning its market prospects amidst increased scrutiny of the company.

The litigation, spearheaded by national shareholder rights firm Hagens Berman, highlights allegations that Soleno misrepresented the safety profile of DCCR. Specifically, claims have emerged that the company minimized serious safety risks observed during clinical trials, including incidents of excess fluid retention among participants. Such accusations not only threaten investor confidence but also cast shadows over the integrity of the clinical data upon which Soleno's marketing strategies depend. The specific charges position this case as a critical challenge not just to Soleno’s financial health but to its credibility within the pharmaceutical industry focused on rare diseases.

Increasing scrutiny on Soleno intensified when activist short seller Scorpion Capital flagged concerning reports regarding children hospitalized for heart failure potentially linked to VYKAT™ XR. Scorpion Capital's critique points to what it deems misleading launch metrics and data integrity issues surrounding the company's claims. As these developments unfold, Soleno must grapple with significant operational and reputational hurdles. Shareholders seeking to participate in the class action lawsuit face a lead plaintiff deadline of May 5, 2026. Hagens Berman emphasizes that affected investors should compile their information to strengthen their claims.

In light of these legal challenges, the future of Soleno Therapeutics' flagship product remains uncertain, posing questions not only about its market entry but also about broader implications for innovation in treating Prader-Willi Syndrome. The outcomes of these legal proceedings are set to influence the company's strategic direction and stakeholder perceptions significantly.

Investors and stakeholders are encouraged to remain engaged with Hagens Berman as the firm seeks justice for affected shareholders, ensuring that their voices are heard in the ongoing discourse surrounding DCCR's commercialization efforts. For further assistance and information, affected investors can reach out via the firm's website or contact number, empowering them to make informed decisions during this tumultuous period.